Target intelligence / Profile preview

Various enteric microorganisms

Molecular classification
Bacteria (Gram-positive), Bacteria (Gram-negative), Fungi, Archaea, Viruses
01

Overview

“Various enteric microorganisms” represents the complex ecosystem of microorganisms inhabiting the gastrointestinal tract. The four dominant bacterial phyla are Firmicutes (Bacillota), Bacteroidetes (Bacteroidota), Actinobacteria (Actinomycetota), and Proteobacteria (Pseudomonadota)[1][4]. Major genera include Bacteroides (constituting about 30% of gut bacteria[4]), Clostridium, Faecalibacterium, Eubacterium, Ruminococcus, Bifidobacterium, Escherichia, and Lactobacillus[1][4]. The family Enterobacteriaceae specifically includes over 30 genera and more than 100 species of Gram-negative bacteria[2], containing both harmless symbionts and pathogens like Salmonella, E. coli, Klebsiella, and Shigella[2]. The microbiota composition varies across different regions of the digestive tract and between individuals, remaining relatively stable within an individual over time but influenced by age, diet, lifestyle, and medication use[1][4].

Other names
Enteric bacteriagut microbiotaintestinal floragut floraintestinal microbiomeenteric microbiome
02

Mechanism of action

Not applicable as a therapeutic target, though the microbiota can be modulated through probiotics, prebiotics, antibiotics, or fecal microbiota transplantation.

03

Biological functions

digestion and nutrient absorptionvitamin synthesisimmune system stimulationinfection preventionmaintenance of gut barrier integritymetabolism of dietary compoundsprotection against pathogenic colonization
04

Disease associations

food-borne illnesses (Salmonella)food-borne illnesses (pathogenic E. coli O157:H7)food-borne illnesses (Campylobacter)antibiotic-associated infections (C. difficile)nosocomial infections (urinary tract infections)nosocomial infections (surgical site infections)nosocomial infections (bacteremia)nosocomial infections (pneumonia)community-acquired infectionsinflammatory bowel disease (dysbiosis)metabolic disorders (dysbiosis)
05

Safety considerations

Too non-specific for therapeutic targetingIncludes beneficial symbiotic organismsIncludes potentially harmful pathogens
06

Interacting drugs

Antibiotics
07

Biomarkers

Microbiota composition analysisspecific pathogen detectionantibiotic resistance profiles

Beyond the preview

Go deeper on Various enteric microorganisms.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Various enteric microorganisms.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call